| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 1,648,747 | RCUS, LKFT, ASMB, KYTX | 13F-HR | 8/3/2026 | 000112329226001034 |
| Q1 2026 | 6 | 2,117,784 | ACLX, RCUS, LKFT, ASMB | 13F-HR | 5/8/2026 | 000112329226000642 |
| Q4 2025 | 6 | 1,935,507 | RCUS, LKFT, ACLX, ASMB | 13F-HR | 2/12/2026 | 000112329226000164 |
| Q3 2025 | 9 | 1,791,467 | LKFT, ACLX, RCUS, ASMB | 13F-HR | 11/13/2025 | 000112329225000642 |
| Q2 2025 | 14 | 1,280,204 | LKFT, ACLX, RCUS, ASMB | 13F-HR | 8/14/2025 | 000112329225000364 |
| Q1 2025 | 14 | 1,181,331 | ACLX, LKFT, RCUS, ASMB | 13F-HR | 5/13/2025 | 000112329225000217 |
| Q4 2024 | 16 | 1,551,148 | ACLX, LKFT, RCUS, ASMB | 13F-HR | 2/13/2025 | 000112329225000079 |
Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each security where the latest filing since 12/18/2024 is a 13D, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Arcus Biosciences, Inc.
13D/A
RCUS · 03969F109
|
24.7% |
8/7/2026
Event 8/5/2026
|
|||
|
Assembly Biosciences, Inc.
13D/A
ASMB · 045396108
|
25.1% |
5/27/2026
Event 5/22/2026
|
|||
|
Arcellx, Inc.
13D/A
ACLX · 03940C100
|
100.0% |
4/28/2026
Event 4/28/2026
|
|||
|
Galapagos NV
13D/A
LKFT · 36315X101
|
29.9% |
1/10/2025
Event 1/7/2025
|
|||
| Gilead Sciences, Inc. | 29.9% | ||||
| Gilead Therapeutics A1 Unlimited Company | 29.9% | ||||
4 other securities where the latest filing is a 13G, the newest filed 2/12/2026. View all